ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) experienced a significant reduction in short interest during November. On November 15th, the total short interest stood at 28,900 shares, marking a substantial decrease of 36.5% from the 45,500 shares reported on October 31st. Given the company's average trading volume of 1,220,000 shares, the short-interest ratio is currently at 0.0 days, indicating that about 2.7% of ZyVersa's stock is sold short.

ZyVersa Therapeutics Stock Performance

As of Friday, shares of NASDAQ:ZVSA opened at $1.07. The stock has recorded a one-year low of $1.03 and a peak of $42.39 over the past year. The fifty-day simple moving average is $1.90, while the two-hundred-day simple moving average stands at $3.13.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for renal and inflammatory diseases. The company is advancing its drug development platforms, including Cholesterol Efflux Mediator VAR 200, which is an injectable drug currently undergoing Phase 2a trials for various renal conditions, such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney diseases. Additionally, the company is working on Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is still in the preclinical stage, targeting inflammatory diseases including acute respiratory syndrome, multiple sclerosis, IgA nephropathy, pancreatic cancer, Parkinson's disease, Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.

ZyVersa, short, interest